Non-peptide endothelin receptor antagonists can antagonize endothelin-induced vasoconstriction, blood pressure increase and vascular smooth muscle cell proliferation, reduce endothelial damage; increase NO synthesis, relax vascular smooth muscle; inhibit platelet aggregation, anti-coagulation, and improve blood rheology characteristics. This product can also inhibit cholesterol synthesis, lower blood lipids, scavenge free radicals, prevent and treat lipid peroxidation damage; affect complement, enhance immune function, and have certain analgesic and antispasmodic effects.

It can improve mental disorders by blocking postsynaptic dopamine receptors in the brain, inhibit the ascending activation system of the brainstem reticular formation, cause sedation, and inhibit the medulla chemoreceptor area to exert an antiemetic effect. This product has weak anti-adrenergic and anti-cholinergic effects, and has anti-depressant and anti-anxiety effects.

This product and its metabolites are cyclic adenosine monophosphate (cAMP) phosphodiesterase III inhibitors (PDEIII inhibitors), which can reduce the degradation of cAMP by inhibiting the activity of phosphodiesterase, thereby increasing the cAMP level in platelets and blood vessels, inhibiting platelet aggregation and vasodilation.